Adamas to Present at Upcoming Healthcare Conferences - Feb. 20, 2020

EMERYVILLE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the following investor conferences:

  • SVB Leerink Global Healthcare Conference on Thursday, February 27 at 9:00-9:25 a.m. ET
    (6:00 a.m. PT)
  • Cowen Annual Healthcare Conference on Wednesday, March 4 at 9:20 a.m.-9:50 a.m. ET
    (6:20 a.m. PT)

The presentations will be webcast live from the investor relations section of the Adamas website at An archived version of the webcast will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.
At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit

Peter Vozzo
Managing Director, Westwicke

Sarah Mathieson
Vice President of Corporate Communications

Primary Logo

Back to news